晚期中年生活方式和AD与非AD连续线上个人的大脑和认知变化
Julie E Oomens1,2, Karly A Cody2,3, Lianlian Du2,4,5,6
1Department of Psychiatry and Neuropsychology School for Mental Health and Neuroscience, Alzheimer Centrum Limburg, Maastricht University Maastricht The Netherlands.
Alzheimer's & dementia (Amsterdam, Netherlands)
|April 17, 2025
概括
在这项研究中,以LIBRA指数衡量的中年后期的生活方式没有显著影响阿尔茨海默病生物标志物或认知轨迹. 生活方式对大脑健康的影响可能需要更多的时间才能显现出来.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 公共卫生 公共卫生
背景情况:
- 研究了中年后期的生活方式与大脑和认知的纵向变化之间的关联.
- 研究了LIBRA指数对生物标志物和认知功能的影响.
- 评估是否生活方式的影响在粉样蛋白阳性和粉样蛋白阴性个体之间有所不同.
研究的目的:
- 为了确定一个复合的生活方式测量 (LIBRA指数) 预测大脑变化 (tau,白质超强度,神经退行) 和认知衰退.
- 评估生活方式因素和认知轨迹之间的关系,调整大脑变化.
- 探索基于粉样蛋白状况的生活方式关联的潜在差异.
主要方法:
- 使用线性混合模型分析了威斯康星州阿尔茨海默氏症预防登记处324名参与者的数据.
- 评估了LIBRA指数与图的变化,白质超强度,神经退行和认知复合物的相关性.
- 比较了粉样蛋白阳性 (A+) 与粉样蛋白阴性参与者的生物标志物和认知轨迹.
主要成果:
- 利布拉指数与生物标志物轨迹 (tau,白质超强度,神经退行) 没有关联.
- 在LIBRA指数和初级认知复合结果轨迹之间没有发现显著的关联.
- 陶氏和神经退行与认知轨迹密切相关,而LIBRA对特定领域的认知产生了不一致的影响.
结论:
- 在研究的年龄和疾病范围内,生活方式没有显著影响阿尔茨海默病或血管生物标志物积累.
- 利布拉指数并不始终与认知轨迹相关,这表明生活方式的影响可能会在更长的时间内表现出来.
- 像tau和神经退行等生物标志物是认知变化的关键驱动因素,独立于该队列的LIBRA指数.
相关概念视频
01:30Cognitive Development During Adulthood
25
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
25
01:26Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
01:30Dementia
68
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
68
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
01:26Aging
24
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
24
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85